Skip to main content

Search

Press Releases

Latest News Releases

May 18, 2019

United States

New Real-World Evidence Highlights Need for Interventions to Improve Outcomes for Patients Who Have Been Diagnosed with Major Depressive Disorder (MDD) and Suicide Ideation or Attempt

May 15, 2019

United States

Janssen to Present Data from Robust Oncology Portfolio and Pipeline at the 2019 ASCO Annual Meeting, Including Best of ASCO Selections

May 14, 2019

United States

Janssen Demonstrates Strong Commitment to Inflammatory Bowel Disease with Data from 25 Abstracts Presented at the 2019 Digestive Disease Week Annual Meeting

May 10, 2019

United States

New Study Finds Chronic Kidney Disease Remains Largely Undiagnosed in Nearly Half of Patients with Type 2 Diabetes and Chronic Kidney Disease

Apr 29, 2019

United States

Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer

Apr 29, 2019

Ireland

Janssen Announces Submission of New Drug Application to U.S. FDA For the First Monthly, Injectable, Two-Drug Regimen of Rilpivirine and Cabotegravir for Treatment of HIV

Apr 15, 2019

Janssen Announces Investigational CAR-T Therapy JNJ-68284528 Granted PRIME Designation by the European Medicines Agency

Apr 14, 2019

Australia

INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

Apr 12, 2019

United States

BALVERSA™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations

Apr 11, 2019

United States

Janssen Presents New Data from First Phase 3 Trial of a Single-Tablet Regimen in a Rapid Initiation Model of Care Demonstrating Safety and Efficacy with SYMTUZA® through 48 Weeks